Xeljanz
Payments companies reported to CMS as associated with Xeljanz. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xeljanz, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xeljanz
These are the largest totals companies reported as associated with Xeljanz. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Rhonda Lambert | San Mateo, CA | Rheumatology | $72,764.43 |
| Allan Gibofsky | New York, NY | Rheumatology | $70,453.23 |
| Theodore Pincus | Chicago, IL | Rheumatology | $60,000.00 |
| Gordon Lam | Charlotte, NC | Rheumatology | $59,425.72 |
| Anthony Turkiewicz | Mountain Brk, AL | Rheumatology | $45,936.78 |
| Hillary Norton | Santa Fe, NM | Rheumatology | $44,593.75 |
| Marla Dubinsky | New York, NY | $44,050.50 | |
| Shanmugapriya Reddy | Riverview, FL | Rheumatology | $40,255.02 |
| Catherine Bakewell | Salt Lake City, UT | Rheumatology | $39,114.24 |
| Sergio Schwartzman | New York, NY | Rheumatology | $38,035.74 |
Prescribed Xeljanz?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.